Novartis’s new heart-failure treatment should cost about 17% less than what Novartis is charging for it in the U.S. because expected wide use of the drug will strain health-care budgets, a nonprofit research group said.
from WSJ.com: US Business http://ift.tt/1UHDzOS
via IFTTT
No comments:
Post a Comment